[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f36gogj3jlzzov":3},{"data":4,"error":8},{"id":5,"documentId":6,"heading":7,"body":8,"slug":9,"name":9,"name_ar":8,"proprietary_name":8,"non_proprietary_name":8,"is_proprietary":8,"active_ingredient":8,"administration_route":8,"available_strength":8,"dosage_form":8,"dose_schedule":8,"drug_unit":8,"is_available_generically":8,"mechanism_of_action":8,"overdosage":8,"warning":8,"species":10,"citations":11,"dose_schedules":25,"available_strengths":33,"label_statements":38,"drug_classes":43,"specialties":44,"medical_conditions":45,"animal_species":52},2232,"fm7eh0jrwhfkhsd0gs67kinn","تيلودرونات",null,"tiludronate",[],[12,18],{"source":13,"licence":14,"source_url":15,"harvested_by":16,"retrieved_at":17},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients","load-reference-corpus.cjs","2026-09-07",{"claims":19,"source":20,"licence":21,"source_url":22,"harvested_by":23,"retrieved_at":24},"Arabic name (heading)","bAItari term layer and label review (model-written, reviewer-confirmed)","original Arabic name","https:\u002F\u002Fbaitari.vet\u002Fdrugs\u002Ftiludronate","apply-label-arabic.cjs label-core-2026-10-23","2026-10-23",[26],{"id":27,"dose_text":28,"species":29,"administration_route":30,"limitation":31,"source_label":32},18033,"A single dose of 1 mg tiludronate disodium\u002Fkg body weight (0.45 mg\u002Flb) administered as an intravenous infusion slowly and evenly over 90 minutes to minimize the risk of adverse reactions.","Horses","Intravenous","Do not use in horses with known hypersensitivity to tiludronate disodium or to mannitol. Do not use in horses with impaired renal function or with a history of renal disease. Bisphosphonates are excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions. Do not use in horses intended for human consumption. NSAIDs should not be used concurrently with TILDREN. Concurrent use of NSAIDs with TILDREN may increase the risk of renal toxicity and acute renal failure. Acute renal failure has been reported in horses concurrently administered NSAIDs and TILDREN within a 48 hour period. Additionally horses concurrently administered TILDREN and NSAIDs in field studies demonstrated a statistically significant increase in serum blood urea nitrogen (BUN) and creatinine concentrations. These elevations were not always associated with clinical signs of renal dysfunction. Therefore, appropriate wash-out periods should be observed between NSAID and TILDREN administration, and BUN and creatinine should be monitored. If treatment for discomfort is required after TILDREN administration, a non-NSAID treatment should be used.","Tildren®",[34],{"id":35,"strength_text":36,"dosage_form":37,"proprietary_name":32,"species":29,"source_label":32},15649,"Each vial of TILDREN contains 500 mg of tiludronic acid (as tiludronate disodium)","Infusion",[39],{"id":40,"kind":41,"statement":42,"species":29,"limitation":31,"source_label":32},26836,"indication","For the control of clinical signs associated with navicular syndrome in horses.",[],[],[46],{"id":47,"documentId":48,"slug":49,"title":50,"heading":51},365,"kfp1dpox9ghnah4mweqea3xd","navicular-syndrome","Navicular syndrome","متلازمة العظم الزورقي",[]]